Sign Out
Co-amoxiclav is indicated for use in the treatment of infections caused by susceptible strains of microorganisms involved in the following: Acute and chronic bronchitis, pneumonia, lung abscess, tonsillitis, sinusitis, otitis media, cystitis, urethritis, pyelonephritis, septic abortion, puerperal sepsis, chancroid, furunculosis, cellulitis, wound infection, intra-abdominal sepsis, osteomyelitis, and post-operative infections. Urinary tract infections.
Susceptible strains of microorganisms would include: Staphylococcus aureus, *Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Viridans group streptococcus, *Enterococcus faecalis, *Enterococcus faecium, Corynebacterium spp, *Bacillus anthracis, Listeria monocytogenes, Clostridium spp, Peptococcus spp, Peptostreptococcus spp.
*Escherichia coli, *Proteus mirabilis, *Proteus vulgaris, *Klebsiella spp, *Salmonella spp, *Shigella spp, Bordetella pertussis, *Yersinia enterocolitica, Gardnerella vaginalis, Brucella spp, *Neisseria gonorrhea, *Moraxella catarrhalis, *Haemophilus influenzae, Haemophilus ducreyi, Pasteurella multocida, Campylobacter jejuni, Vibrio cholera, Helicobacter pylori, Legionella spp, *Bacteriodesspp, *Fusobacterium spp.
*-including β-lactamase-producing strains which are resistant to ampicillin or amoxicillin.
